AstraZeneca PLC is in advanced talks to pay more than $5 billion for little-known biotech company Acerta Pharma BV and its promising cancer compound, according to people familiar with the … The transaction provides AstraZeneca with Acerta’s potential best-in-class irreversible oral Bruton's tyrosine kinase (Btk) inhibitor, acalabrutinib (ACP-196), currently in Phase III development for B-cell blood cancers and in Phase I/II clinical trials in multiple solid tumors. Because of this intense collaboration with AstraZeneca, Acerta Clinical Operations play a significant role in drug development in early oncology. document.getElementById('cloak15130').innerHTML += '
' + addy15130+'<\/a>'; Acerta Pharma is a member of the AstraZeneca Group and together we work on our combined early oncology pipeline compounds. Because of this intense collaboration with AstraZeneca, Acerta Clinical Operations play a significant role in drug development in early oncology. SUZHOU, China and ROCKVILLE, MD., August 18, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its interim results for the six months ended June 30, 2020. //-->. To encourage tradeshow attendees’ engagement with the booth, Cognition crafted an interactive walkthrough of Acerta Pharma’s Elevate Clinical Trials and oncology pipeline. AstraZeneca to Buy Stake in Acerta Pharma Deal is latest move by U.K. drugmaker to rebuild its pipeline AstraZeneca is to take a majority stake in a closely held biotech company. “We are excited to announce this strategic transaction with AstraZeneca, which is a testament to the value inherent in Acerta and acalabrutinib,” said David Johnson, Chief Executive Officer of Acerta. Vincera is expected to have approximately$60 million at closing to fund clinical and preclinical development pipeline. The New England Journal of Medicine recently published positive results of early clinical testing of the drug, which is seen as a rival to Johnson & Johnson (JNJ) - Get Report and AbbVie's The company is also seeking to strengthen its pipeline to make up for a loss in patent protection by the end of 2017 on three key products -- heartburn medication Nexium, Seroquel for schizophrenia, and cholesterol medicine Crestor -- that account for nearly 40% of its revenue. © 2021 TheStreet, Inc. All rights reserved. AstraZeneca shares were up 1.45% in London at 4,480 pence, for a total market value of around £56.8 billion ($85.4 billion). Option for AstraZeneca to Acquire Remaining 45% Ownership in Acerta for Up to $3 Billion OSS, TheNetherlands & REDWOOD CITY, CA, USA I December 17, 2015 I Acerta Pharma B.V. (Acerta), a clinical-stage biopharmaceutical company, announced today that it has entered into a definitive agreement with AstraZeneca whereby AstraZeneca will acquire a majority stake in Acerta. You need JavaScript enabled to view it. Action Alerts PLUS is a registered trademark of TheStreet, Inc. Atara Biotherapeutics’s robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer, autoimmune and viral diseases. Company profile page for Acerta Pharma BV including stock price, company news, press releases, executives, board members, and contact information Acerta’s lead molecule, acalabrutinib (ACP-196), is a selective and potent inhibitor of Btk. ... partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology. Phase I/II data showing a favorable safety profile and strong efficacy in relapsed/refractory chronic lymphocytic leukemia patients was presented at the American Society of Hematology Annual Meeting & Exposition in December 2015, with simultaneous publication in the New England Journal of Medicine. In February 2016, AstraZeneca made a multibillion-dollar investment in Acerta Pharma for 55% ownership, driven by the lead investigational Bruton tyrosine kinase (BTK) inhibitor, acalabrutinib and the opportunity to build out its haematology/oncology pipeline. This email address is being protected from spambots. AstraZeneca said it aims to bring six new cancer medicines to patients by 2020, with a pipeline focused on ovarian, lung, breast and blood cancers. Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. It was not immediately clear how big a stake the VC holds or whether it is selling out completely or retaining 45% of its holding for now. During the reporting period, Ascentage Pharma made significant … The agreement also includes options which, if exercised, provide the opportunity for Acerta shareholders to sell, and AstraZeneca to buy, the remaining 45% of shares in Acerta. “AstraZeneca brings tremendous expertise and resources that will help us maximize the potential of acalabrutinib as we continue down multiple development paths in both hematologic malignancies and solid tumors. Prior to joining Mirum, Dr. Tucker served as chief operating officer at Acerta Pharma LLC where he supported the first U.S. approval and launch of Calquence in 2017. Acerta Pharma BV is a Biotech company that combines two technology platforms in drug discovery and development: the Covalent Technology Platform and the Multiparametric Phosphoflow Cytometry Platform. Our broad pipeline of next-generation medicines is focused on four main disease areas - ovarian, lung, breast and haematological cancers. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. Together with AstraZeneca and their global footprint, we believe we will further accelerate our global clinical development program and maximize the future commercial potential of acalabrutinib. Collaborating with Acerta helps to accelerate our global clinical development program for APG-2575," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. Acerta Pharma Announces Strategic Transaction with AstraZeneca. (ABBV) - Get Report Imbruvica and as a potential blockbuster treatment. Jennifer was the Global Regulatory Lead for the Calquence (acalabrutinib) US NDA in R/R MCL which was granted accelerated approval in 2017, as well as for subsequent Calquence global filings in R/R MCL as well as CLL/SLL. Under the terms of the agreement, AstraZeneca will acquire 55% of the entire issued share capital of Acerta for total consideration of $4.0 billion, comprised of upfront consideration of $2.5 billion and further unconditional consideration of $1.5 billion to be paid either on receipt of the first regulatory approval for acalabrutinib for any indication in the US, or the end of 2018, depending on which is first. In Thursday's statement, Soriot said the Acerta investment "is consistent with our long-term growth and reflects the role targeted business development plays in our business model.". Acerta shareholders also have an option to sell, and AstraZeneca has an option to buy, the remaining 45% stake for about $3 billion. Collaborating with Acerta helps to accelerate our global clinical development program for APG-2575," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective, Report Package: “Drug the Undruggable” Technologies, RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective, T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis, PipelineReview.com is powered by La Merie Business Intelligence, For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01, La Merie Publishing - Ulrich Martin | Carrer Garraf, 20, Bajos, 1a | 08870 Sitges | Spain T +49-7934-6839 668 | F +49-3212-1267 572 | Email This email address is being protected from spambots. IO pipeline explores new pathways to enhance immune response. Acerta Pharma serves as AstraZeneca’s haematology research and development arm. Acerta founded. Acerta's acalabrutinib is being tested as a treatment for various types of leukemia, lymphoma and other cancers. AstraZeneca Is Buying a Majority Stake in Acerta Pharma for $4 Billion. The company has operations in Oss, the Netherlands and multiple U.S. sites. This included designing the information architecture, the interactive interfaces, and crafting collateral materials for a fully-tailored booth experience. OSS, TheNetherlands & REDWOOD CITY, CA, USA I December 17, 2015 I Acerta Pharma B.V. (Acerta), a clinical-stage biopharmaceutical company, announced today that it has entered into a definitive agreement with AstraZeneca whereby AstraZeneca will acquire a majority stake in Acerta. Upon close of the transaction, Acerta will initially be a majority-owned subsidiary of AstraZeneca. Stockholders of Vincera ... cofounder of Acerta Pharma … addy15130 = addy15130 + 'lamerie' + '.' + 'com'; We look forward to working closely with the AstraZeneca team to realize our mutual goal of transforming cancer care.”, “AstraZeneca has a strong track record of leadership in oncology and has shown a commitment to advancing the next generation of important therapeutics,” said Wayne Rothbaum, Executive Chairman of Acerta. AstraZeneca partners with like-minded science-led companies to advance the discovery and development of therapies to address unmet need. It sees Acerta's cancer drug as "potentially transformational for the company's future, becoming the sixth growth platform.". If AstraZeneca acquires the remaining shares of the company in the future, Acerta would become a wholly-owned subsidiary. var path = 'hr' + 'ef' + '='; On Dec 11, 2015, the Wall. “We believe AstraZeneca is the best partner to help advance our research to improve patient outcomes across a range of hematologic cancers and solid tumors.”. AstraZeneca plc AZN confirmed, in response to a speculation, that it is exploring strategic options with Acerta Pharma BV. Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer. The buyer said it expects the acquisition to be "moderately dilutive" to core earnings in the near term. He is a founder of Acerta Pharma, a member of the AstraZeneca Group, and has previously served as the Chief Executive and Medical Officer. Prior to joining Kronos Bio, she was at Acerta Pharma, a member of the AstraZeneca Group, as Head of Global Regulatory Science. 2013 • Developed ibrutinib from preclinical through Phase 2 in < 3 years • All three Phase 2 studies garnered Break-Through Designation and Accelerated Approvals. The options can be exercised at various points in time, conditional on the first approval of acalabrutinib in both the US and Europe and when the extent of the commercial opportunity has been fully established, at a price of approximately $3.0 billion net of certain costs and payments incurred by AstraZeneca and net of agreed future adjusting items, using a pre-agreed pricing mechanism. The transaction will be accounted for as a business combination and is expected to be complete by the end of the first quarter of 2016, subject to regulatory and customary closing conditions. AstraZeneca to Acquire 55% Ownership of Acerta for $4 Billion Total Cash Consideration, Option for AstraZeneca to Acquire Remaining 45% Ownership in Acerta for Up to $3 Billion. var addy15130 = 'info' + '@'; Acerta Pharma is a member of the AstraZeneca Group and together we work on our combined early oncology pipeline compounds. Goldman, Sachs & Co. is acting as lead financial advisor and Jefferies LLC is serving as joint financial advisor to Acerta. Acerta is also developing ACP-319, a novel isoform-selective inhibitor of phosphoinositide 3-kinase (PI3K) delta. Jefferies previously acted as exclusive placement agent to Acerta on a $375 million private placement in May 2015. Acerta is based in Oss in the Netherlands, and has its U.S. headquarters in Redwood City, Calif. At least one of its shareholders in a venture capitalist firm, Dutch investor Biogeneration Ventures, which bought into the company in 2013. AstraZeneca plans to complete the Acerta deal by the end of the first quarter and fund the initial $2.5 billion payment from cash and debt. The deal will give AstraZeneca a potential blockbuster cancer drug, and an option to buy the other 45% of the company later for about $3 billion. Acalabrutinib (ACP 196) is an orally administered, second generation, agammaglobulinaemia tyrosine kinase inhibitor (also known as Bruton's tyrosine kinase or Management Team’s Contribution. It is scheduled to publish 2015 full-year results, along with its guidance for 2016, in early February. Dr Hamdy has +20 years of clinical research experience in pharmaceutical drug development, seven of which were in academic medical research. Morgan, Lewis & Bockius and Nauta Dutilh are serving as legal counsel to Acerta. These are being targeted through four key platforms – immuno-oncology, the genetic drivers of cancer and resistance, … //